Back close

De Novo designing of HDAC inhibitors in cancer therapy

Publication Type : Journal Article

Thematic Areas : Center for Computational Engineering and Networking (CEN)

Publisher : International Journal of Pharmaceutical Science and Health Care

Source : International Journal of Pharmaceutical Science and Health Care, Volume 2, p.59–66 (2012)

Campus : Amritapuri, Coimbatore

School : School of Biotechnology, School of Engineering

Center : Computational Engineering and Networking

Department : Center for Computational Engineering and Networking (CEN), Sciences

Year : 2012

Abstract : HDACs are enzymes found in eukaryotes. It removes the acetyl group from the lysine residue on the N-terminal regions of histone proteins and the process is called histone deacetylation. It results in the increased positive charge on histones. The DNA possesses negatively charged sugar-phosphate backbone; therefore the positively charged histones bind more firmly to the DNA. This makes the DNA unavailable for the transcription factors and eventually leads to the gene silencing. Rather than histone proteins, HDACs ...

Cite this Research Publication : C. P. Anju, Anusooya, N. J., Deeasree, M., Deepak, O. M., and P. K. Krishnan Namboori, “De Novo designing of HDAC inhibitors in cancer therapy”, International Journal of Pharmaceutical Science and Health Care, vol. 2, pp. 59–66, 2012

Admissions Apply Now